Overall rank by patents
#26,103
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Diasorin S.p.a.
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2017–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
10
Total patents granted
6
CPC technology areas
17.0
Avg claims per patent
+50%
5-year filing velocity
The verdict
Diasorin holds 10 US patents across 6 technology areas, rank #26,103 of 50,000 tracked assignees.
- #26,103
- of 50,000 US assignees by volume
- Top 70%
- by Innovation Score (29.4/100)
- 17.0
- avg claims per patent
- +50%
- filing velocity, last 5 yrs
Portfolio overview
Diasorin S.p.a. has been granted 10 US utility patents between 2017 and 2023, placing Diasorin S.p.a. at rank #26,103 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.0 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Diasorin S.p.a. is one of the more focused assignees in the PatentsView dataset. By volume, Diasorin sits between Deutsches Rheuma-forschungszentrum Berlin (10 patents, rank #26,099) and Dna2.0, Inc. (10 patents, rank #26,107) - the closest US assignees by grant volume. The composite Innovation Score of 29.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 4 in the 2015–2019 window, a +50% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Diasorin S.p.a.'s 17.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Diasorin S.p.a. against peers pursuing similar technology classes.
Who files at Diasorin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Deutsches Rheuma-…
DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN
10 patents
- Devar Entertainme…
DEVAR ENTERTAINMENT LIMITED
10 patents
- Devon Energy
DEVON ENERGY CORPORATION
10 patents
- Diagnostica Stago
DIAGNOSTICA STAGO
10 patents
- Digital Check
DIGITAL CHECK CORP.
10 patents
- Digiwin
DIGIWIN CO., LTD.
10 patents
- Discourse AI
DISCOURSE.AI, INC.
10 patents
- DNA2 0
DNA2.0, INC.
10 patents
- Diasorin S p A ◀
DIASORIN S.p.A.
10 patents
What this shows Diasorin holds 10 patents at rank #26,103, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Diasorin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 70% higher than 30% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 10.0% |
| 2018 | 1 | 10.0% |
| 2019 | 2 | 20.0% |
| 2020 | 1 | 10.0% |
| 2021 | 3 | 30.0% |
| 2022 | 1 | 10.0% |
| 2023 | 1 | 10.0% |
Which technologies does Diasorin S.p.a. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Diasorin S.p.a. hold?
Diasorin S.p.a. holds 10 US granted patents filed between 2017 and 2023, spanning 6 technology areas.
What is Diasorin S.p.a.'s Innovation Score?
Diasorin S.p.a. has an Innovation Score of 29.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Diasorin S.p.a. focus on?
Diasorin S.p.a.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 6 patents. The company has filed patents in 6 CPC subclasses total.
Is Diasorin S.p.a.'s patent filing rate increasing or decreasing?
Diasorin S.p.a.'s recent filing velocity is +50% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Diasorin S.p.a.'s patents?
Diasorin S.p.a.'s patents average 17.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Diasorin S.p.a. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Diasorin's 10 grants land it in the top 70% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Diasorin ranks #26,103 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.